Literature DB >> 21989987

Significant mobilization of both conventional and regulatory T cells with AMD3100.

Leslie S Kean1, Sharon Sen, Olusegun Onabajo, Karnail Singh, Jennifer Robertson, Linda Stempora, Aylin C Bonifacino, Mark E Metzger, Daniel E L Promislow, Joseph J Mattapallil, Robert E Donahue.   

Abstract

In this study, we used the rhesus macaque model to determine the impact that AMD3100 has on lymphocyte mobilization, both alone and in combination with G-CSF. Our results indicate that, unlike G-CSF, AMD3100 substantially mobilizes both B and T lymphocytes into the peripheral blood. This led to significant increases in the peripheral blood content of both effector and regulatory T-cell populations, which translated into greater accumulation of these cells in the resulting leukapheresis products. Notably, CD4(+)/CD25(high)/CD127(low)/FoxP3(+) Tregs were efficiently mobilized with AMD3100-containing regimens, with as much as a 4.0-fold enrichment in the leukapheresis product compared with G-CSF alone. CD8(+) T cells were mobilized to a greater extent than CD4(+) T cells, with accumulation of 3.7 ± 0.4-fold more total CD8+ T cells and 6.2 ± 0.4-fold more CD8(+) effector memory T cells in the leukapheresis product compared with G-CSF alone. Given that effector memory T-cell subpopulations may mediate less GVHD compared with other effector T-cell populations and that Tregs are protective against GVHD, our results indicate that AMD3100 may mobilize a GVHD-protective T-cell repertoire, which would be of benefit in allogeneic hematopoietic stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21989987      PMCID: PMC3242720          DOI: 10.1182/blood-2011-06-359331

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  Design issues of randomized phase II trials and a proposal for phase II screening trials.

Authors:  Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

2.  Hematologic recovery and survival of lymphoma patients after autologous stem-cell transplantation: comparison of bone marrow and peripheral blood progenitor cells.

Authors:  P Brice; J P Marolleau; P Pautier; J Makke; D Cazals; H Dombret; M F D'Agay; M Benbunan; C Gisselbrecht
Journal:  Leuk Lymphoma       Date:  1996-08

3.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

4.  Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.

Authors:  Mary Eapen; Mary M Horowitz; John P Klein; Richard E Champlin; Fausto R Loberiza; Olle Ringdén; John E Wagner
Journal:  J Clin Oncol       Date:  2004-11-01       Impact factor: 44.544

5.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Elin Rodger; Hal E Broxmeyer; Christine Dehner; Karin Badel; Gary Calandra; Jeff Christensen; Brent Wood; Thomas H Price; David C Dale
Journal:  Transfusion       Date:  2005-03       Impact factor: 3.157

6.  Expression of chemokine receptors CXCR4 and CCR5 in HIV-1-infected and uninfected individuals.

Authors:  M A Ostrowski; S J Justement; A Catanzaro; C A Hallahan; L A Ehler; S B Mizell; P N Kumar; J A Mican; T W Chun; A S Fauci
Journal:  J Immunol       Date:  1998-09-15       Impact factor: 5.422

7.  Peripheral blood CD34+ cells differ from bone marrow CD34+ cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor.

Authors:  R E Donahue; M R Kirby; M E Metzger; B A Agricola; S E Sellers; H M Cullis
Journal:  Blood       Date:  1996-02-15       Impact factor: 22.113

8.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor.

Authors:  W I Bensinger; C H Weaver; F R Appelbaum; S Rowley; T Demirer; J Sanders; R Storb; C D Buckner
Journal:  Blood       Date:  1995-03-15       Impact factor: 22.113

9.  Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.

Authors:  Linhua Zou; Brian Barnett; Hana Safah; Vincent F Larussa; Melina Evdemon-Hogan; Peter Mottram; Shuang Wei; Odile David; Tyler J Curiel; Weiping Zou
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

10.  Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.

Authors:  Z S Pavletic; S S Joshi; S J Pirruccello; S R Tarantolo; J Kollath; E C Reed; P J Bierman; J M Vose; P I Warkentin; T G Gross; K Nasrati; J O Armitage; A Kessinger; M R Bishop
Journal:  Bone Marrow Transplant       Date:  1998-01       Impact factor: 5.483

View more
  34 in total

1.  Discordance in lymphoid tissue recovery following stem cell transplantation in rhesus macaques: an in vivo imaging study.

Authors:  Robert E Donahue; Sharat Srinivasula; Naoya Uchida; Insook Kim; Alexis St Claire; Gorka Duralde; Paula DeGrange; Marisa St Claire; Richard C Reba; Aylin C Bonifacino; Allen E Krouse; Mark E Metzger; Chang H Paik; H Clifford Lane; John F Tisdale; Michele Di Mascio
Journal:  Blood       Date:  2015-10-22       Impact factor: 22.113

Review 2.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

3.  Preexisting malignancy abrogates the beneficial effects of CXCR4 blockade during sepsis.

Authors:  Wenxiao Zhang; Deena B Chihade; Jianfeng Xie; Ching-Wen Chen; Kimberly M Ramonell; Zhe Liang; Craig M Coopersmith; Mandy L Ford
Journal:  J Leukoc Biol       Date:  2020-01-27       Impact factor: 4.962

4.  Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.

Authors:  Mark A Schroeder; Michael P Rettig; Sandra Lopez; Stephanie Christ; Mark Fiala; William Eades; Fazia A Mir; Jin Shao; Kyle McFarland; Kathryn Trinkaus; William Shannon; Elena Deych; Jinsheng Yu; Ravi Vij; Keith Stockerl-Goldstein; Amanda F Cashen; Geoffrey L Uy; Camille N Abboud; Peter Westervelt; John F DiPersio
Journal:  Blood       Date:  2017-03-14       Impact factor: 22.113

Review 5.  Haploidentical SCT: the mechanisms underlying the crossing of HLA barriers.

Authors:  Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

Review 6.  Harnessing bone marrow resident regulatory T cells to improve allogeneic stem cell transplant outcomes.

Authors:  Laetitia Le Texier; Katie E Lineburg; Kelli P A MacDonald
Journal:  Int J Hematol       Date:  2016-12-10       Impact factor: 2.490

7.  Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells.

Authors:  Fabio Di Giacomo; Daniel Lewandowski; Eric Cabannes; Vanessa Nancy-Portebois; Maurice Petitou; Serge Fichelson; Paul-Henri Romeo
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

8.  Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.

Authors:  Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem
Journal:  Blood Adv       Date:  2018-05-08

9.  Collection of hematopoietic CD34 stem cells in rhesus macaques using Spectra Optia.

Authors:  Lynn D Haynes; Jennifer Coonen; Jennifer Post; Kevin Brunner; Debra Bloom; Peiman Hematti; Dixon B Kaufman
Journal:  J Clin Apher       Date:  2016-08-31       Impact factor: 2.821

10.  Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats.

Authors:  X Hu; T Okabayashi; A M Cameron; Y Wang; M Hisada; J Li; L C Raccusen; Q Zheng; R A Montgomery; G M Williams; Z Sun
Journal:  Am J Transplant       Date:  2016-02-26       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.